Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1971 Sep;68(9):2121–2123. doi: 10.1073/pnas.68.9.2121

Decrease of the 3,4-Dihydroxyphenylalanine (DOPA) Decarboxylase Activities in Human Erythrocytes and Mouse Tissues after Administration of DOPA

Suresh S Tate 1,2, Richard Sweet 1,2, Fletcher H McDowell 1,2, Alton Meister 1,2
PMCID: PMC389365  PMID: 5289372

Abstract

Human erythrocytes have been found to contain appreciable amounts of DOPA decarboxylase (EC 4.1.1.26) activity. The enzyme activity in erythrocytes from patients with Parkinson's disease who were treated with DOPA was significantly lower than that of untreated patients and of normal individuals. Administration of the drug to mice led to a marked decrease of DOPA decarboxylase in liver and kidney, but not of the brain enzyme. The findings thus indicate that administration of DOPA leads to a decrease in peripheral DOPA decarboxylase, an effect that is expected to be of benefit in DOPA therapy of patients with Parkinson's disease. Peripheral DOPA decarboxylase concentration also decreases in mice after short periods of fasting; the findings suggest that the peripheral enzyme activities may be affected by various nutritional and perhaps hormonal influences, which may be partially responsible for the observed fluctuations in the motor abilities of Parkinsonian patients receiving constant doses of the drug. Study of DOPA decarboxylase activity in erythrocytes may be useful in following changes in patients receiving DOPA therapy and may also be of general interest and value in investigations of catecholamine metabolism in man.

Keywords: Parkinson's disease, brain, liver, kidney, catecholamines

Full text

PDF
2121

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartholini G., Pletscher A. Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. J Pharm Pharmacol. 1969 May;21(5):323–324. doi: 10.1111/j.2042-7158.1969.tb08258.x. [DOI] [PubMed] [Google Scholar]
  2. Bryson G., Bischoff F. Dopamine transport in human blood. Clin Chem. 1970 Apr;16(4):312–317. [PubMed] [Google Scholar]
  3. HOLTZ P. Role of L-DOPA decarboxylase in the biosynthesis of catecholamines in nervous tissue and the adrenal medulla. Pharmacol Rev. 1959 Jun;11(2 Pt 2):317–329. [PubMed] [Google Scholar]
  4. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  5. Lloyd K., Hornykiewicz O. Occurrence and distribution of L-DOPA decarboxylase in the human brain. Brain Res. 1970 Sep 16;22(3):426–428. doi: 10.1016/0006-8993(70)90489-0. [DOI] [PubMed] [Google Scholar]
  6. SCHOTT H. F., CLARK W. G. DOPA decarboxylase inhibition through the interaction of coenzyme and substrate. J Biol Chem. 1952 May;196(1):449–462. [PubMed] [Google Scholar]
  7. Siegfried J. Deux ans d'expérience avec la L-DOPA associée à un inhibiteur de la décarboxylase. Rev Neurol (Paris) 1970 Apr;122(4):243–248. [PubMed] [Google Scholar]
  8. Sourkes T. L. Dopa decarboxylase: substrates, coenzyme, inhibitors. Pharmacol Rev. 1966 Mar;18(1):53–60. [PubMed] [Google Scholar]
  9. Vogel W. H., McFarland H., Prince L. N. Decarboxylation of 3,4-dihydroxyphenylalanine in various human adult and fetal tissues. Biochem Pharmacol. 1970 Feb;19(2):618–620. doi: 10.1016/0006-2952(70)90220-0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES